+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Amyotrophic Lateral Sclerosis Treatment Market - Global Forecast 2026-2032- Product Image
Amyotrophic Lateral Sclerosis Treatment Market - Global Forecast 2026-2032- Product Image
New

Amyotrophic Lateral Sclerosis Treatment Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 193 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5305507
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Amyotrophic Lateral Sclerosis (ALS) Treatment Market is entering a pivotal phase as scientific innovation, regulatory evolution, and shifting commercialization frameworks redefine therapy development and patient care. Senior leaders must adapt to accelerating advances while maintaining operational efficiency and compliance in an increasingly complex environment.

Market Snapshot: ALS Treatment Market Size and Growth

The ALS Treatment Market expanded from USD 733.06 million in 2025 to USD 785.76 million in 2026 and is projected to reach USD 1.18 billion by 2032, reflecting a robust CAGR of 7.14%. Strong revenue growth underscores continued demand for innovative treatment modalities and market resilience despite supply chain and regulatory shifts. Growth is being fueled by clinical breakthroughs, evolving payer expectations, and a diversifying therapeutic pipeline. Organizations positioned across these value drivers are set to capture new market opportunities as geographic and payer landscapes diversify.

Scope & Segmentation

This report delivers detailed analysis of drivers, barriers, and future opportunities shaping the ALS Treatment Market. It drills down into commercial, clinical, and regulatory domains, ensuring strategic insights on key segments and technologies relevant for forward-thinking stakeholders:

  • Treatment: Covers both traditional medications (such as Dextromethorphan/Quinidine, Edaravone, Riluzole, Tofersen) and emerging therapies including gene and stem cell interventions. These reflect evolving clinical endpoints and potential to move beyond symptom management.
  • Type: Analyzes Familial ALS and Sporadic ALS, addressing genetic and epidemiological factors that impact trial design, therapy personalization, and deployment of diagnostic biomarkers.
  • Treatment Stage: Investigates advanced, mid, and early disease management, recognizing the need for tailored clinical metrics, adaptive designs, and customized payer models for each phase.
  • Route of Administration: Evaluates Intrathecal, Intravenous, and Oral channels, taking into account system readiness, patient preferences, and infrastructure implications vital to product success.
  • Distribution Channel: Examines hospital and retail pharmacies, highlighting logistics and specialty pharmacy factors that determine therapy accessibility and patient adherence.
  • Regions Covered: Includes Americas, Europe, Middle East & Africa, and Asia-Pacific, each informed by unique regulatory pathways, reimbursement protocols, and commercial launch dynamics.
  • Technology Integration: Addresses leading commercial trends in companion diagnostics, adaptive trial design approaches, and the incorporation of real-world evidence for enhanced clinical validation and payer confidence.

Key Takeaways for Senior Decision-Makers

  • The ALS treatment sector is evolving from traditional symptom-focused products toward mechanism-targeted innovations, led by advances in gene therapies and antisense oligonucleotides that encourage a shift to personalized interventions and disease modification.
  • Evolving regulatory frameworks facilitate accelerated and conditional product approvals. This adaptability is especially relevant for therapies supported by surrogate endpoints and ongoing evidence commitments.
  • Utilization of digital biomarkers and real-world monitoring are increasingly central to demonstrating clinical outcomes and informing payer coverage and pricing strategies.
  • Operational complexity requires adaptable supply chains and scalable manufacturing footprints, ensuring both market access and resilience against disruptions at launch or during scale-up.
  • Segmented, region-specific launch and access strategies, along with targeted engagement with local payers and regulators, advance product uptake and leverage the diversity of global reimbursement landscapes.
  • Collaboration across biotech, pharma, and clinical networks drives faster development and broader patient reach, expediting both innovation and consistent market delivery of advanced treatments.

Tariff Impact on ALS Therapeutic Supply Chain

Changes in United States tariff policy have created new cost dynamics and sourcing considerations for manufacturing ALS therapies. In response, many companies are re-examining sourcing frameworks, implementing greater visibility across supply tiers, and exploring domestic production and vertical integration for high-value components. These shifts place a premium on forward-looking procurement, agile manufacturing partnerships, and alignment with regulatory authorities, ensuring both uninterrupted supply and compliant access as tariff uncertainty continues.

Methodology & Data Sources

Analysis for this report is based on interviews with key experts across clinical, regulatory, and supply chain functions, complemented by a structured review of published literature, regulatory publications, and corporate sources. Scenario modeling and expert feedback ensure a comprehensive and validated risk assessment aligned to senior leadership priorities.

Why This Report Matters

  • Enables strategic planning with granular insights on evolving regulatory, scientific, and commercial forces affecting the ALS Treatment Market.
  • Empowers organizational leadership to optimize development decisions, invest in resilient manufacturing, and enhance global market access strategies based on region-specific intelligence.
  • Delivers actionable frameworks for investment prioritization, product launch sequencing, and assessment of long-term therapeutic impact by segment and geography.

Conclusion

The ALS Treatment Market is redefining itself through applied innovation, regulatory flexibility, and renewed supply chain focus. Forward-thinking organizations integrating these elements will be best placed to capture value and drive improved patient outcomes as industry transformation advances.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment
8.1. Medication
8.1.1. Dextromethorphan/Quinidine
8.1.2. Edaravone
8.1.3. Riluzole
8.1.4. Tofersen
8.2. Therapies
8.2.1. Gene Therapy
8.2.2. Stem Cell Therapy
9. Amyotrophic Lateral Sclerosis Treatment Market, by Type
9.1. Familial ALS
9.2. Sporadic ALS
10. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment Stage
10.1. Advanced Stage Treatment
10.2. Early Stage Treatment
10.3. Mid Stage Treatment
11. Amyotrophic Lateral Sclerosis Treatment Market, by Route of Administration
11.1. Intrathecal
11.2. Intravenous
11.3. Oral
12. Amyotrophic Lateral Sclerosis Treatment Market, by Distribution Channel
12.1. Hospital Pharmacies
12.2. Retail Pharmacies
13. Amyotrophic Lateral Sclerosis Treatment Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Amyotrophic Lateral Sclerosis Treatment Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Amyotrophic Lateral Sclerosis Treatment Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Amyotrophic Lateral Sclerosis Treatment Market
17. China Amyotrophic Lateral Sclerosis Treatment Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AB Science SA
18.6. Alector, Inc.
18.7. Amylyx Pharmaceuticals, Inc.
18.8. Apotex Inc.
18.9. Aquestive Therapeutics, Inc.
18.10. Ascend Pharmaceuticals LLC
18.11. AstraEureka Pharmaceuticals
18.12. Biogen Inc.
18.13. BrainStorm Cell Limited
18.14. Cipla Limited
18.15. CorestemChemon Inc.
18.16. Coya Therapeutics, Inc.
18.17. Cytokinetics, Incorporated
18.18. Dewpoint Therapeutics, Inc.
18.19. DR. REDDY’S LABORATORIES LIMITED
18.20. F. Hoffmann-La Roche Ltd
18.21. Genervon Biopharmaceuticals, LLC
18.22. GlaxoSmithKline PLC
18.23. Implicit Bioscience Ltd.
18.24. Ionis Pharmaceuticals, Inc.
18.25. ITF Pharma, Inc.
18.26. Kringle Pharma, Inc.
18.27. Mitsubishi Tanabe Pharma Corporation
18.28. Neurimmune AG
18.29. Novartis AG
18.30. ONO PHARMACEUTICAL CO., LTD.
18.31. Orion Corporation
18.32. Orphazyme A/S
18.33. Otsuka Pharmaceutical Co., Ltd.
18.34. Pfizer, Inc.
18.35. Sanofi SA
18.36. Sun Pharmaceutical Industries Ltd
18.37. Teva Pharmaceutical Industries Ltd.
18.38. Treeway B.V.
18.39. Viatris Inc.
18.40. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DEXTROMETHORPHAN/QUINIDINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DEXTROMETHORPHAN/QUINIDINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DEXTROMETHORPHAN/QUINIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TOFERSEN, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TOFERSEN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TOFERSEN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY FAMILIAL ALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY FAMILIAL ALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY FAMILIAL ALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPORADIC ALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPORADIC ALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPORADIC ALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ADVANCED STAGE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ADVANCED STAGE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ADVANCED STAGE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EARLY STAGE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EARLY STAGE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EARLY STAGE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MID STAGE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MID STAGE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MID STAGE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRATHECAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 65. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
TABLE 66. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
TABLE 67. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
TABLE 68. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 69. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
TABLE 70. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 71. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 72. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
TABLE 74. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
TABLE 75. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
TABLE 76. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 80. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
TABLE 82. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
TABLE 84. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 85. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 96. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
TABLE 98. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
TABLE 99. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
TABLE 100. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 101. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
TABLE 102. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 103. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 104. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
TABLE 106. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
TABLE 107. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
TABLE 108. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 109. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
TABLE 110. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 111. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 112. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
TABLE 114. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
TABLE 115. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
TABLE 116. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 117. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
TABLE 118. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 119. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
TABLE 131. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
TABLE 132. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
TABLE 133. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 134. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
TABLE 135. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 136. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
TABLE 139. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
TABLE 140. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
TABLE 141. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 142. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
TABLE 143. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 144. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
TABLE 147. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
TABLE 148. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 150. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
TABLE 151. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 152. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
TABLE 155. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
TABLE 156. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
TABLE 157. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 158. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
TABLE 159. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 160. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 161. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 162. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
TABLE 163. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
TABLE 164. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
TABLE 165. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 166. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
TABLE 167. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 168. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 169. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 170. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
TABLE 171. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
TABLE 172. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
TABLE 173. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 174. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
TABLE 175. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 176. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 177. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 179. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
TABLE 180. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
TABLE 181. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
TABLE 182. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 183. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
TABLE 184. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 185. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 187. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
TABLE 188. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
TABLE 189. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
TABLE 190. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 191. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
TABLE 192. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 193. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Amyotrophic Lateral Sclerosis Treatment market report include:
  • AB Science SA
  • Alector, Inc.
  • Amylyx Pharmaceuticals, Inc.
  • Apotex Inc.
  • Aquestive Therapeutics, Inc.
  • Ascend Pharmaceuticals LLC
  • AstraEureka Pharmaceuticals
  • Biogen Inc.
  • BrainStorm Cell Limited
  • Cipla Limited
  • CorestemChemon Inc.
  • Coya Therapeutics, Inc.
  • Cytokinetics, Incorporated
  • Dewpoint Therapeutics, Inc.
  • DR. REDDY’S LABORATORIES LIMITED
  • F. Hoffmann-La Roche Ltd
  • Genervon Biopharmaceuticals, LLC
  • GlaxoSmithKline PLC
  • Implicit Bioscience Ltd.
  • Ionis Pharmaceuticals, Inc.
  • ITF Pharma, Inc.
  • Kringle Pharma, Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Neurimmune AG
  • Novartis AG
  • ONO PHARMACEUTICAL CO., LTD.
  • Orion Corporation
  • Orphazyme A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Treeway B.V.
  • Viatris Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages193
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 785.76 Million
Forecasted Market Value ( USD ) by 2032 $ 1180 Million
Compound Annual Growth Rate7.1%
Regions CoveredGlobal
No. of Companies Mentioned37

Related Topics

Related Reports

Amyotrophic Lateral Sclerosis Market Report and Forecast 2025-2034 - Product Image

Amyotrophic Lateral Sclerosis Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Amyotrophic Lateral Sclerosis Treatment Market Report by ALS Type, Drug Type, Diagnosis Type, Treatment, Distribution Channel, Countries and Company Analysis 2025-2033 - Product Image

Amyotrophic Lateral Sclerosis Treatment Market Report by ALS Type, Drug Type, Diagnosis Type, Treatment, Distribution Channel, Countries and Company Analysis 2025-2033

  • Report
  • 200 Pages
  • Global
From
Amyotrophic Lateral Sclerosis - Global Strategic Business Report - Product Image

Amyotrophic Lateral Sclerosis - Global Strategic Business Report

  • Report
  • 183 Pages
  • Global
From
Amyotrophic Lateral Sclerosis Treatment Market Report by ALS Type, Drug Type, Diagnosis Type, Treatment, Distribution Channel, and Region 2025-2033 - Product Image

Amyotrophic Lateral Sclerosis Treatment Market Report by ALS Type, Drug Type, Diagnosis Type, Treatment, Distribution Channel, and Region 2025-2033

  • Report
  • 140 Pages
  • Global
From
Amyotrophic Lateral Sclerosis Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Amyotrophic Lateral Sclerosis Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From

About the Amyotrophic Lateral Sclerosis Drug Market

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder that affects the motor neurons in the brain and spinal cord. As a result, patients experience muscle weakness, paralysis, and eventually death. The ALS drug market is a subset of the Central Nervous System (CNS) drug market, which includes drugs used to treat neurological disorders such as Alzheimer’s, Parkinson’s, and Multiple Sclerosis. The ALS drug market is relatively small compared to other CNS drug markets, but it is growing due to increased awareness and research into the disease. The ALS drug market is composed of both generic and branded drugs. Generic drugs are typically used to treat the symptoms of ALS, while branded drugs are used to slow the progression of the disease. Currently, there are several companies that are actively researching and developing new treatments for ALS, including Biogen, Novartis, and Sanofi. Additionally, there are several companies that are focused on providing generic drugs to treat the symptoms of ALS, such as Mylan and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.